<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glyburide (glibenclamide): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glyburide (glibenclamide): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Glyburide (glibenclamide): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12513" href="/d/html/12513.html" rel="external">see "Glyburide (glibenclamide): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F176698"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Glynase [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867062"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-GlyBURIDE;</li>
<li>Diabeta [DSC];</li>
<li>PMS-GlyBURIDE [DSC];</li>
<li>TEVA-GlyBURIDE;</li>
<li>TRIA-GlyBURIDE</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F176748"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Sulfonylurea</li></ul></div>
<div class="block doa drugH1Div" id="F176703"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Micronized glyburide tablets are not bioequivalent to conventional glyburide tablets; dosage adjustments may be required when switching between glyburide formulations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> who cannot take metformin. Sulfonylureas are associated with a greater risk of hypoglycemia than other noninsulin antidiabetic agents; if one is chosen, a sulfonylurea other than glyburide with a lower relative risk of hypoglycemia (eg, glipizide, glimepiride) is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2023','lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2023','lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conventional tablets (Diaβeta):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 1.25 to 5 mg once daily administered with the first main meal; in patients whose glycemic levels are close to goal, use lower initial doses (eg, 1.25 to 2.5 mg once daily) to reduce the risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10454950','lexi-content-ref-10605995','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10454950','lexi-content-ref-10605995','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment:</i> May increase in increments of ≤2.5 mg/day every 1 to 4 weeks if needed to achieve glycemic goals; usual maintenance dose: 2.5 to 10 mg/day in 1 or 2 divided doses (maximum: 20 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10454950','lexi-content-ref-Wexler.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10454950','lexi-content-ref-Wexler.1','lexi-content-ref-Manu.1'])">Ref</a></span>).<b> Note:</b> For some patients, especially those receiving &gt;10 mg/day, glycemic response may be improved with twice-daily dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Micronized tablets (Glynase PresTab):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 0.75 to 3 mg once daily administered with the first main meal.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment:</i> May increase in increments of ≤1.5 mg/day every 1 to 4 weeks if needed to achieve glycemic goals; usual maintenance dose: 0.75 to 6 mg/day in 1 or 2 divided doses (maximum: 12 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10454950','lexi-content-ref-Wexler.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10454950','lexi-content-ref-Wexler.1','lexi-content-ref-Manu.1'])">Ref</a></span>).<b> Note:</b> For some patients, especially those receiving &gt;6 mg/day, glycemic response may be improved by administering in 2 divided doses.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy</b>
<b>:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990695"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: Avoid use due to long duration of action and risk of accumulation of renally excreted active metabolites causing prolonged hypoglycemia. If a sulfonylurea is chosen, agents with a shorter half-life and inactive metabolites (eg, glipizide) may be preferred to reduce the risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25249672','lexi-content-ref-26239457','lexi-content-ref-23067652','lexi-content-ref-28465376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25249672','lexi-content-ref-26239457','lexi-content-ref-23067652','lexi-content-ref-28465376'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use due to long duration of action and risk of accumulation of renally excreted active metabolites causing prolonged hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27967230','lexi-content-ref-10692277','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27967230','lexi-content-ref-10692277','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use due to long duration of action and risk of accumulation of renally excreted active metabolites causing prolonged hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27967230','lexi-content-ref-10692277','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27967230','lexi-content-ref-10692277','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>
<b>Oral:</b> Avoid use due to long duration of action and risk of accumulation of renally excreted active metabolites causing prolonged hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Oral:</b> Avoid use due to long duration of action and risk of accumulation of renally excreted active metabolites causing prolonged hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988016"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, use conservative initial and maintenance doses.</p></div>
<div class="block doe drugH1Div" id="F176704"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Avoid use due to increased risk of hypoglycemia. Agents other than sulfonylureas are preferred in older adults; if a sulfonylurea is needed, one with a lower relative risk of hypoglycemia (eg, glipizide, glimepiride) is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2023'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F176666"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Epigastric fullness (≤2%), heartburn (≤2%), nausea (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%; including erythema, maculopapular rash, morbilliform rash, pruritus, urticaria)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Disulfiram-like reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia, hyponatremia, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Diuresis (minor)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic failure, hepatitis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Accommodation disturbance, angioedema, arthralgia, blurred vision, bullous rash, erythema multiforme, exfoliative dermatitis, increased serum transaminases, myalgia, vasculitis</p></div>
<div class="block coi drugH1Div" id="F176681"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to glyburide or any component of the formulation; type 1 diabetes mellitus or diabetic ketoacidosis, with or without coma; concomitant use with bosentan.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to any sulfonylurea or sulfonamide; diabetic precoma or coma, stress conditions (eg, severe infections, trauma, surgery); liver disease or frank jaundice; renal impairment; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F176663"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse reactions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS), have not supported an association. In patients with established atherosclerotic cardiovascular disease (ASCVD), other agents are preferred (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished or debilitated patients, and in patients with severe renal and hepatic impairment, adrenal and/or pituitary insufficiency; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Use IR formulations after surgery to minimize the potential effects of bypassing stomach and proximal small bowel with gastric bypass or more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy (Apovian 2015). ER formulations may have altered release and absorption patterns after gastric bypass or sleeve gastrectomy (but not gastric band). Compared to control, T<sub>max</sub> in a gastric bypass cohort administered tolbutamide was significantly shorter (1.4 ± 1.8 vs 5.1 ± 1.7 hours; <i>P </i>&lt; 0.001), while C<sub>max</sub> and AUC<sub>0-</sub>
<sub>∞</sub> were not altered (Tandra 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Hypoglycemia: Use an antidiabetic agent without the potential for hypoglycemia if possible; hypoglycemia may occur after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (gastric bypass is most effective, followed by sleeve and finally band) (Korner 2009; Peterli 2012). First-phase insulin secretion and hepatic insulin sensitivity have been shown to be significantly improved in the immediate days after gastric bypass and sleeve gastrectomy. The restorative effects of these procedures on peripheral insulin sensitivity may occur later in the 3- to 12-month period postsurgery (Mingrone 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Evaluate risk vs benefit and consider alternative therapy after gastric bypass, sleeve gastrectomy, and gastric banding; weight gain may occur (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose-6-phosphate dehydrogenase deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: The metabolism and excretion of glyburide may be slowed in patients with renal impairment and its active metabolites may accumulate in advanced renal insufficiency (Snyder 2004). If hypoglycemia should occur, it may be prolonged. Use of glyburide is generally not recommended in chronic kidney disease (ADA [Tuttle 2014]; Alsahli 2015; KDOQI [Nelson 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glyburide tablet formulations: <i>Micronized</i> glyburide tablets are <b>not</b> bioequivalent to <i>conventional </i>glyburide tablets; retitration should occur if patients are being transferred to a different glyburide formulation (eg, micronized-to-conventional or vice versa) or from other hypoglycemic agents.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with diabetic ketoacidosis (DKA) or patients with type 1 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Consider temporary discontinuation of noninsulin antidiabetic agents and initiation or continuation of insulin therapy during hospitalization (ADA 2023). In noncritically ill hospitalized patients, continued use of sulfonylureas may be considered if there are no contraindications, regular nutritional intake is expected, and blood glucose is well controlled; close monitoring and subsequent dosage adjustments are recommended (ADA/AACE [Moghissi 2009]; Bogun 2013; Inzucchi 2006). If sulfonylureas are used, those of shorter duration (eg, glipizide, glimepiride) are preferred (ADA 2023).</p></div>
<div class="block dosfc drugH1Div" id="F22123827"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Micronized formulation: Glynase</p></div>
<div class="block foc drugH1Div" id="F176673"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glynase: 1.5 mg [DSC], 3 mg [DSC], 6 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.25 mg, 1.5 mg, 2.5 mg, 3 mg, 5 mg, 6 mg</p></div>
<div class="block geq drugH1Div" id="F176659"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F176683"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (glyBURIDE Micronized Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $0.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $0.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (glyBURIDE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 mg (per each): $0.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867063"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diabeta: 2.5 mg [DSC], 5 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block adm drugH1Div" id="F176678"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with meals at the same time each day. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.</p></div>
<div class="block use drugH1Div" id="F176677"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p></div>
<div class="block mst drugH1Div" id="F176756"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">GlyBURIDE may be confused with glipiZIDE, Glucotrol</p>
<p style="text-indent:-2em;margin-left:4em;">Diaβeta may be confused with Zebeta</p>
<p style="text-indent:-2em;margin-left:4em;">Micronase may be confused with Microzide</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Avoid use due to increased risk of hypoglycemia. If a sulfonylurea is needed, one with a lower relative risk of hypoglycemia (eg, glipizide, glimepiride) is preferred (ADA 2023; Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F176743"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (major), CYP3A4 (minor), OATP1B1/1B3 (SLCO1B1/1B3); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F176668"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: GlyBURIDE may enhance the hepatotoxic effect of Bosentan. GlyBURIDE may decrease the serum concentration of Bosentan. Bosentan may decrease the serum concentration of GlyBURIDE. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colesevelam: May decrease the serum concentration of GlyBURIDE. Management: Administer glyburide at least 4 hours prior to colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: GlyBURIDE may increase the serum concentration of Fluvastatin. Fluvastatin may increase the serum concentration of GlyBURIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of GlyBURIDE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Sulfonylureas. Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs or symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Miconazole (Oral) may increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitiglinide: May enhance the adverse/toxic effect of Sulfonylureas.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RaNITIdine (Withdrawn from US Market): May enhance the hypoglycemic effect of GlyBURIDE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: May enhance the hypoglycemic effect of GlyBURIDE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F24257169"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Ethanol may cause rare disulfiram reactions. Management: Monitor patients.  </p></div>
<div class="block rep_considerations drugH1Div" id="F56016194"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Sulfonylureas are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020).</p></div>
<div class="block pri drugH1Div" id="F176684"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Glyburide crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. Additional adverse maternal and fetal events have been noted in some studies and may be influenced by maternal glycemic control and/or differences in study design (Bertini 2005; Ekpebegh 2007; Joy 2012; Langer 2000; Langer 2005). According to the manufacturer, if glyburide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of glyburide may be altered (Hebert 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Glyburide has been evaluated for the treatment of gestational diabetes mellitus; however, because glyburide crosses the placenta, long-term safety data are not available, and adverse events have been observed, glyburide should not be recommended as an initial alternative therapy (ACOG 190 2018; ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than glyburide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F1699343"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Glyburide may be present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Using information from a case report, the relative infant dose (RID) of glyburide was calculated to be 0.08% using a milk concentration of 7.3 ng/mL, providing an estimated daily infant dose via breast milk of 0.001 mg/kg/day. This milk concentration was obtained following maternal administration of very large doses of glyburide (up to 90 mg/day) for the treatment of permanent neonatal diabetes mellitus (PNDM) caused by a KCNJ11 (Kir6.2) mutation throughout pregnancy. Glyburide was also detected in the serum of the breastfeeding infant 6 days after birth (Myngheer 2014). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). Glyburide was not detected in breast milk following short-term maternal use with standard doses (Feig 2005); however, chronic therapy was not evaluated.</p>
<p style="text-indent:-2em;margin-left:2em;">Appropriate glycemic control is required for the establishment of lactation in patients with diabetes mellitus (Anderson 2018). Breastfeeding provides metabolic benefits to mothers with diabetes mellitus as well as their infants; therefore, breastfeeding is encouraged (ACOG 201 2018; ADA 2023; Blumer 2013). According to the manufacturer, due to the potential for hypoglycemia in the breastfeeding infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother; however, other sources note that glyburide may be used in patients who are breastfeeding; infants should be monitored for hypoglycemia (Anderson 2018; Blumer 2013; WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F176685"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy based on American Diabetes Association recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F176671"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Signs and symptoms of hypoglycemia, urine glucose test, fasting blood glucose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F176674"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults with diabetes (AACE [Samson 2023], ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F176662"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites</p></div>
<div class="block phk drugH1Div" id="F176680"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Serum insulin levels begin to increase 15-60 minutes after a single dose </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: ≤24 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Significant within 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: Extensive, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; forms metabolites (weakly active)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Variable among oral dosage forms</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Diaβeta: 10 hours; Glynase PresTab: ~4 hours; may be prolonged with renal or hepatic impairment </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Adults: 2-4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (50%) and urine (50%) as metabolites</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F176686"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diatab | Euglucon | Glibil | Glynase | Melix | Micronase | Mini Glynase</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Benclamid | Daonil | Diabemin | Euglucon | G.o.n. | Gardoton | Glaturin | Glentor | Glibediab | Glibemida | Glibenclamida | Glibenclamida ahimsa | Glibenclamida denver farma | Glibenclamida fabra | Glibenclamida gen med | Glibenclamida puntanos | Glibenclamida vannier | Glidanil | Gliptid | Glitral | N14 glibe | Pira</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Dia-eptal | Euglucon | Glibenclamid genericon pharma | Glucobene | Glucostad | Normoglucon</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Glimel | Semi daonil</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Daosin | Diabeles | Diacon | Diben | Dibenol | Dicon | Gilemal | Glabin | Gluban | Glucon | Gluconil | Glucotab</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bevoren | Daonil | Euglucon</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Fairglib | Glibenclamide tm | Hemi-daonil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Glibenclamid | Maninil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aglucil | Benclamin | Clamiben | Daonil | Diaben | Diabetty's | Diabexil | Diabinil | Euglucon | Furp glibenclamida | Glibenclamida | Glibenclamon | Glibeneck | Glibex | Glibexil | Glicamida | Glicamin | Gliconil | Glionil | Glucosil | Iquego glibenclamida | Lisaglucon | Lqfex glibenclamida | Nilclamida | Uni gliben</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Gli-basan | Gli-basan semi | Glibenclamid-cophar | Glibenorm | Glibesifar | Semi daonil</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Glibenclamida Generis | Glibenclamide tm</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Clais | Daonil | Euglusid | Glibenclamida | Mezalit</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Glibenhexal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Euglucon | Glibenclamida | Glibenclamida MK | Glibens | Glucinex | Gluicon</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Betanase | Calabren aps | Daonil | Euglucon | Gilemal | Glibasan | Glibenhexal | Glucobene | Maninil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Azuglucon | Bastiverit | Daonil | Dia-basf | Duraglucon n | Euglucon | Glib | Glib abz | Gliben | Gliben lich | Gliben-puren n | Glibenbeta | Glibenclamid | Glibenclamid al | Glibenclamid basic | Glibenclamid sandoz | Glibenclamid temmler | Glibendoc | Glibenhexal | Glimidstada | Glucoremed | Glukoreduct | Glukovital | Glycolande n | Humedia | Jutaglucon | Maninil | Orabetic | Praeciglucon | Semi daonil | Semi gliben puren n | Semi-Euglucon</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Armoniol | Daonil | Diabetop | Euglucon | Glibelam | Glibencil | Glibenclamid | Glibenclamida | Glibenil | Gliboral | Glichem | Gluben | Glucamida | Glucoven | Lufranclamida | Nor-Clamida | Norboral | Su-Ka</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diabesulf | Edulco | Euglucon | Gliben | Glibenclamida | Glibenclamida MK | Glicem | Libraglucil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Betanaze | Daonil | Gilemal | Glib s-ratiopharm | Glibenclamid | Glibenclamid awd | Glucobene | Maninil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diaben | Euglucon | Glibecon | Gliben | Gluben | Semi daonil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Glucolon | Norglicem</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Clamide | Daonil | Diaben</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglamin | Euglucon | Gilemid | Origlucon</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucan | Glibenclamide arrow | Glibenclamide eg | Hemi-daonil | Miglucan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abbenclamide | Calabren | Daonil | Diabetamide | Euglucon | Glibenclamide berk | Glibenclamide cox | Glibenclamide dc | Glibenclamide kent | Lederglib | Libanil | Malix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Deroctyl | Diabefar | Euglycon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo glyburide | Clamide | Cp-Gliben | Daomid | Daonil | Euglucon | Gliban | Gliben | Gliboral | Glifil | Glimel | Glitisol | Glucoben | Melix | Qualibenmide | Semi daonil | Semi-Euglucon | Xeltic</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Glibenclamid Genericon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Euglucon | Gilemal | Glucobene | Maninil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Clamega | Condiabet | Daonil | Euglucon | Fimediab | Glidanal | Glimel | Gluconic | Gluconin | Glulo | Glyamid | Harmida | Hartmida | Latibet | Padonil | Prodiabet | Prodiamel | Renabetic | Semi-Euglucon | Tiabet | Trodeb</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Daonil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Glibetic | Gluben</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Afdiex | Betanase | Codica | D-con | Daonil | Daorid | Diabentil | Diabetnil | Euglucon | G-nil | Glibet | Gliconil | Glinil | Glucosafe | Glunil | Glyboral | Glybovin | Semi codica | Semi daonil | Semi glyboral | Semi-Euglucon</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Daoneer | Glibemid | Glibenawa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Gliben | Gliboral</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diatab | Euglucon | Glibemide | Glibesyn | Glibil | Glucana | Glucomid | Glunil | Melix | Riveclamide</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Benclart | Benclart taiyo | Bratogen | Cramiton | Damsel | Daonil | Entrezon | Euglucon | Euglucon chugai | Euglucon yamanouchi | Glibenclamide nichiiko | Glypinart | Margleid | Opeamin | Pamilcon | Pamilcon yamakawa | Pamilicon | Seogrumin | Seogrumin choseido</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Betanase | Daonil | Dicon | Glemide | Glibetics | Glibil | Gliboral | Glicon | Glimide | Glitisol | Glycomin | Melix | Nogluc</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dangbinol | Daonil | Daonil semi | Diabet | Euglucon | Glisulin | Glynase Prestab | Suraben</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diatab | Doabetic | Euglucon | Glynase | Micronase</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo glyburide | Daonil | Euglucon | Glibamid | Gliboral | Glidiabet | Melix</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo gliburid | Betanase | Daonil | Euglucon | Gilemal | Glibasan | Glibenclamid awd | Glucobene | Glyboral | Maninil</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Glibenhexal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apo gliburid | Betanase | Daonil | Euglucon | Gilemal | Glibasan | Gliben | Glibenclamid | Glibenclamid awd | Glucobene | Maninil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Benclamid | Daonil | Glidiabet | Glipharm | Hemi-daonil</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apogly | Biojara | Brucen | Daonil | Dibetid | Diglexol | Euglucon | Glemicid | Glibenclamid brissa | Glibenclamida | Glibenclamida g.i | Glibenclamida gi s | Glibenclamida Innovare | Glibenclamida Teva | Glibenil | Glibenval | Glicavin | Glifarcal | Glihexal | Glikeyer | Glipar | Glucal | Glucoven | Insusym | Lawazin | Mibeclag | Norboral | Ocrix | Reglusan | Secrusol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Benil | Claben | Clamide | D.B.T | Daonil | Debtan | Diabitol | Dibelet | Dyanil | Euglucon | Glibemid | Gliben | Glibenclamide Pharmaniaga | Glibesyn | Glimide | Haminil</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Adnil | Bgnil | Cladyl | Clamide | Clezide | Glanil | Glemid | Glipil | Heonil | Rotaclamide | Sanclamide | Zunabetis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Glibenclamide Actavis | Glibenclamide Alpharma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Glibenclamid | Glibenclamid abz | Glibenklamid recip | Hexaglucon</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-glibenclamide | Daonil | Gliben | Semi daonil</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Doabetic</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diabetglin | Euglucon | Glibefar | Glibemlip | Glibenclamida | Glibepharm | Gliciron | Glidiabet | Gliren</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Allase | Amecladin | Bendix | Benglycon | Benmide | Daonil | Debtan | Diabent | Euglamid | Euglotab | Euglucon | Eundin | Gliben | Glibenclamide Winthrop | Glimide | Gluban | Glymod | Hyporex | Insol | Lodulce | Melix | Orabetic | Sucron | Usa lab glibenclamide | Vamsler glibenclamide</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Benil | Daonil | Diabeta | Diabetone | Diamide | Dicon | Euglucon | Glabinol | Glaonil | Gliben | Glicon | Glifen | Glukil | Maclamide | Pharmide | Pligliben | Semi glicon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euclamin | Euglucon | Gilemal | Glibenclamid al</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Diabeta | Glyburide | Glyburide (Micronized) | Glyburide micro | Glynase Prestab | Micronase</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Glibenclamida | Semi daonil | Semi-Euglucon</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diameg | Euglucon | Glibamida | Gliben | Glibencil | Glibenclamida empa | Glibenclamida pasteur | Glidanil | Glidiabet | Indoprin | Normaprol | Vincadil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diaben | Diatab | Doabetic | Glynase (Julphar) | Mini-Glynase (Julphar)</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gilemal | Glibenclamid arena | Glibenclamid atb | Glibenclamid lph | Glibetic | Gluben</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Antibet | Betanase | Daonil | Diab control | Gilemal | Glamid | Glibenclamid | Glibenclamid-teva | Glibex | Glidanil | Glimidstada | Glucobene | Maniglid | Maninil | Statiglin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo glyburide | Daonil | Diatab | Doabetic | Euglucon | Glibemide | Glibil | Glymide | Glynase | Micronase | Novo glyburide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Glibenclamid ratiopharm | Glibenklamid recip</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo glyburide | Benil | Clamide | Daonil | Dibelet | Euglucon | Glibemid | Glibesyn | Glicon | Glimel | Glimide | Glyboral</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Glibenklamid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Glucobene | Maninil</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Benclamide | Benclamin | Benlacon | Bnil-5g | Bowadon | Cytagon | Daobenes | Daonil | Daono | Debtan | Deonil | Diabenol | Dibelet | Dibenil | Dibesin | Eubemide | Euglucon | Eunil | Glamide | Glenclamide | Glibecon | Glibenam | Glibenese | Glibenil | Glibesyn | Glibetic | Glibic | Glimide | Gluben | Glucomide | Glucon | Gluzo | Locose | Manoglucon | Neogil | Pinnil | Semi-diabenol | Semi-Euglucon | Sibenax | Sinil | Sugril | T.o.nil | Unil-5 | Upcon | Xeltic | Zibenax</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diabenyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dianorm | Diyaben | Gliben</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antiglucon | Apo glyburide | Daonil | Deglucon | Diaben | Diabenlyse | Diabetin | Diabitan | Diabitin | Diomin | Entrezon | Euglucon | Glamide | Gleuton | Gliben | Glibide | Glimel | Glimide | Gliucon | Gluli | Pertanzin | Semi-Euglucon | Shintan | Tantell | Yichentan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Betanase | Gilemal | Glibamid | Glibenclamid | Glibenclamid Rivopharm | Maniglid | Manil | Maninil</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Betanase | Diaben | Diabeta | Dias | Glamide | Glibex 5</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diabeton | Diaclamid | Euglucon | Glibenclamida | Glibexan | Glimida | Glyburide</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Euglucon | Glibenclamida | Glibenil | Gliciron | Glucamida</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Plariche</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Daonil | Diacare | Euglucon | Glibenclamide oethmaan | Glyben | Glycomin | Norton-glibenclamide | Rolab-glibenclamide</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Betanase | Clamide | Daonil | Diolin | Dyanil | Glamide | Glemide | Glibex | Glinil | Glycoben | Glycomin | Kaonil | Metagliben</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Glamide | Glitisol | Variglyben</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18539916">
<a name="18539916"></a>ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients With Type 2 Diabetes. <i>N Engl J Med.</i> 2008;358(24):2560-2572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/18539916/pubmed" id="18539916" target="_blank">18539916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26239457">
<a name="26239457"></a>Alsahli M, Gerich JE. Hypoglycemia in patients with diabetes and renal disease. <i>J Clin Med</i>. 2015;4(5):948-964. doi: 10.3390/jcm4050948.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/26239457/pubmed" id="26239457" target="_blank">26239457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins – Obstetrics. ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes – 2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding. <i>Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi:10.1210/jc.2014-3415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16318615">
<a name="16318615"></a>Bertini AM, Silva JC, Taborda W, et al. Perinatal Outcomes and the Use of Oral Hypoglycemic Agents. <i>J Perinat Med.</i> 2005;33(6):519-523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/16318615/pubmed" id="16318615" target="_blank">16318615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23688537">
<a name="23688537"></a>Bogun M, Inzucchi SE. Inpatient management of diabetes and hyperglycemia. <i>Clin Ther</i>. 2013;35(5):724-733. doi:10.1016/j.clinthera.2013.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/23688537/pubmed" id="23688537" target="_blank">23688537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10454950">
<a name="10454950"></a>DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. <i>Ann Intern Med</i>. 1999;131(4):281-303. doi:10.7326/0003-4819-131-4-199908170-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/10454950/pubmed" id="10454950" target="_blank">10454950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.1">
<a name="Sanofi.1"></a>DiaBeta (glyburide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.2">
<a name="Sanofi.2"></a>Diabeta (glyburide) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A Review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17305787">
<a name="17305787"></a>Ekpebegh CO, Coetzee EJ, van der Merwe L, et al. A 10-Year Retrospective Analysis of Pregnancy Outcome in Pregestational Type 2 Diabetes: Comparison of Insulin and Oral Glucose-Lowering Agents. <i>Diabet Med.</i> 2007;24(3):253-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/17305787/pubmed" id="17305787" target="_blank">17305787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8092211">
<a name="8092211"></a>Elliott BD, Schenker S, Langer O, et al. Comparative Placental Transport of Oral Hypoglycemic Agents in Humans: A Model of Human Placental Drug Transfer. <i>Am J Obstet Gynecol.</i> 1994;171(3):653-660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/8092211/pubmed" id="8092211" target="_blank">8092211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16043722">
<a name="16043722"></a>Feig DS, Briggs GG, Kraemer JM, et al. Transfer of Glyburide and Glipizide Into Breast Milk. <i>Diabetes Care.</i> 2005;28(8):1851-1855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/16043722/pubmed" id="16043722" target="_blank">16043722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551019">
<a name="14551019"></a>Gabbe SG, Graves CR. Management of Diabetes Mellitus Complicating Pregnancy. <i>Obstet Gynecol.</i> 2003;102(4):857-868.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/14551019/pubmed" id="14551019" target="_blank">14551019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract.</i> 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9935017">
<a name="9935017"></a>Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction. <i>J Am Coll Cardiol.</i> 1999;33(1):119-124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/9935017/pubmed" id="9935017" target="_blank">9935017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2117383">
<a name="2117383"></a>Gavin JR 3rd. Glyburide: New Insights Into Its Effects on the Beta Cell and Beyond - Introduction. <i>Am J Med.</i> 1990;89(2A):1S-2S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/2117383/pubmed" id="2117383" target="_blank">2117383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27967230">
<a name="27967230"></a>Gianchandani RY, Neupane S, Iyengar JJ, Heung M. Pathophysiology and management of hypoglycemia in end-stage renal disease patients: a review. <i>Endocr Pract</i>. 2017;23(3):353-362. doi:10.4158/EP161471.RA<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/27967230/pubmed" id="27967230" target="_blank">27967230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PAI.1">
<a name="PAI.1"></a>Glyburide tablets, USP [prescribing information]. Greenville, SC: Pharmaceutical Associates, Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pharmacia.1">
<a name="Pharmacia.1"></a>Glynase PresTab [package insert]. New York, NY: Pharmacia &amp; Upjohn; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19295505">
<a name="19295505"></a>Hebert MF, Ma X, Naraharisetti SB, et al. Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis For Better Clinical Practice. <i>Clin Pharmacol Ther.</i> 2009;85(6):607-614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/19295505/pubmed" id="19295505" target="_blank">19295505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17079764">
<a name="17079764"></a>Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. <i>N Engl J Med</i>. 2006;355(18):1903-1911. doi:10.1056/NEJMcp060094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/17079764/pubmed" id="17079764" target="_blank">17079764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22644829">
<a name="22644829"></a>Joy S, Roman A, Istwan N, et al. The Effect of Maternal Obesity on Pregnancy Outcomes of Women With Gestational Diabetes Controlled With Diet Only, Glyburide, or Insulin. <i>Am J Perinatol.</i> 2012;29(8):643-648.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/22644829/pubmed" id="22644829" target="_blank">22644829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman MS, Briscoe VJ, Clark N, et al; Consensus Development Conference on Diabetes and Older Adults. Diabetes in older adults: a consensus report. <i>J Am Geriatr Soc</i>. 2012;60(12):2342-2356. doi:10.1111/jgs.12035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10692277">
<a name="10692277"></a>Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. <i>Am J Kidney Dis</i>. 2000;35(3):500-505. doi:10.1016/s0272-6386(00)70204-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/10692277/pubmed" id="10692277" target="_blank">10692277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11036118">
<a name="11036118"></a>Langer O, Conway D, Berkus M, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. <i>N Engl J Med. </i>2000;343(16):1134-1138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/11036118/pubmed" id="11036118" target="_blank">11036118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15672015">
<a name="15672015"></a>Langer O, Yogev Y, Xenakis EM, et al. Insulin and Glyburide Therapy: Dosage, Severity Level of Gestational Diabetes, and Pregnancy Outcome. <i>Am J Obstet Gynecol.</i> 2005;192(1):134-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15672015/pubmed" id="15672015" target="_blank">15672015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27568471">
<a name="27568471"></a>Mingrone G, Cummings DE. Changes of insulin sensitivity and secretion after bariatric/metabolic surgery. <i>Surg Obes Relat Dis</i>. 2016;12(6):1199-1205. doi:10.1016/j.soard.2016.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/27568471/pubmed" id="27568471" target="_blank">27568471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19454396">
<a name="19454396"></a>Moghissi ES, Korytkowski MT, DiNardo M, et al; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. <i>Endocr Pract</i>. 2009;15(4):353-369. doi:10.4158/EP09102.RA<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/19454396/pubmed" id="19454396" target="_blank">19454396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25231897">
<a name="25231897"></a>Myngheer N, Allegaert K, Hattersley A, et al. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. <i>Diabetes Care</i>. 2014;37(12):3333-3335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/25231897/pubmed" id="25231897" target="_blank">25231897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23067652">
<a name="23067652"></a>National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. <i>Am J Kidney Dis.</i> 2012;60(5):850-886. doi:10.1053/j.ajkd.2012.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/23067652/pubmed" id="23067652" target="_blank">23067652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28465376">
<a name="28465376"></a>Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. <i>J Am Soc Nephrol</i>. 2017;28(8):2263-2274. doi:10.1681/ASN.2016121372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/28465376/pubmed" id="28465376" target="_blank">28465376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3931464">
<a name="3931464"></a>Pearson JG. Pharmacokinetics of Glyburide. <i>Am J Med.</i> 1985;79(3B):67-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/3931464/pubmed" id="3931464" target="_blank">3931464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi:10.1007/s11695-012-0622-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461903">
<a name="15461903"></a>Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15461903/pubmed" id="15461903" target="_blank">15461903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10605995">
<a name="10605995"></a>Riddle MC. Oral pharmacologic management of type 2 diabetes. <i>Am Fam Physician</i>. 1999;60(9):2613-2620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/10605995/pubmed" id="10605995" target="_blank">10605995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1907234">
<a name="1907234"></a>Schwinghammer TL, Antal EJ, Kubacka RT, et al. Pharmacokinetics and Pharmacodynamics of Glyburide in Young and Elderly Nondiabetic Adults. <i>Clin Pharm.</i> 1991;10(7):532-538.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/1907234/pubmed" id="1907234" target="_blank">1907234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461745">
<a name="15461745"></a>Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. <i>Semin Dial</i>. 2004;17(5):365-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15461745/pubmed" id="15461745" target="_blank">15461745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3090865">
<a name="3090865"></a>Sonnenblick M, Shilo S. Glibenclamide Induced Prolonged Hypoglycaemia. <i>Age Ageing. </i>1986;15(3):185-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/3090865/pubmed" id="3090865" target="_blank">3090865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23222033">
<a name="23222033"></a>Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. <i>Ann Surg</i>. 2013;258(2):262-269. doi:10.1097/SLA.0b013e31827a0e82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/23222033/pubmed" id="23222033" target="_blank">23222033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25249672">
<a name="25249672"></a>Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. <i>Diabetes Care</i>. 2014;37(10):2864-2883. doi:10.2337/dc14-1296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/25249672/pubmed" id="25249672" target="_blank">25249672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9742976">
<a name="9742976"></a>UK Prospective Diabetes Study (UKPDS) Group. Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33). <i>Lancet. </i>1998;352(9131):837-853.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/9742976/pubmed" id="9742976" target="_blank">9742976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9742977">
<a name="9742977"></a>UK Prospective Diabetes Study (UKPDS) Group. Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). <i>Lancet.</i> 1998;352(9131):854-865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/9742977/pubmed" id="9742977" target="_blank">9742977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17596481">
<a name="17596481"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/17596481/pubmed" id="17596481" target="_blank">17596481</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8494 Version 501.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
